Cargando…

Successful use of rivaroxaban achieving therapeutic anti-factor xa levels in a morbidly obese patient with acute intermediate-high risk pulmonary embolism

Direct oral anticoagulants (DOACs) have become the standard of care for acute and long-term therapy for venous thromboembolism (VTE) due to their efficacy and safety profiles. The 2021 International Society on Thrombosis and Haemostasis guidelines recommend using standard DOAC dosages in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dah, Kingsley, Porres-Aguilar, Mateo, la Rosa, Alan De, Prakash, Swathi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV) 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421569/
https://www.ncbi.nlm.nih.gov/pubmed/37576730
http://dx.doi.org/10.1590/1677-5449.202300562
_version_ 1785089010803146752
author Dah, Kingsley
Porres-Aguilar, Mateo
la Rosa, Alan De
Prakash, Swathi
author_facet Dah, Kingsley
Porres-Aguilar, Mateo
la Rosa, Alan De
Prakash, Swathi
author_sort Dah, Kingsley
collection PubMed
description Direct oral anticoagulants (DOACs) have become the standard of care for acute and long-term therapy for venous thromboembolism (VTE) due to their efficacy and safety profiles. The 2021 International Society on Thrombosis and Haemostasis guidelines recommend using standard DOAC dosages in patients with BMI >40 kg/m(2) or weight >120 kg. Use of DOACs remains uncertain in morbidly obese patients with VTE, including acute PE. A morbidly obese woman in her 30s who presented with acute worsening of dyspnea was diagnosed with acute intermediate-high risk acute pulmonary embolism and concomitant proximal deep vein thrombosis, constituting a clinically challenging scenario for treating her with rivaroxaban. Standard doses of rivaroxaban for acute and extended phase treatment of venous thromboembolism in individuals with morbid obesity at BMI>70 kg/m(2) may be effective, and safe.
format Online
Article
Text
id pubmed-10421569
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)
record_format MEDLINE/PubMed
spelling pubmed-104215692023-08-12 Successful use of rivaroxaban achieving therapeutic anti-factor xa levels in a morbidly obese patient with acute intermediate-high risk pulmonary embolism Dah, Kingsley Porres-Aguilar, Mateo la Rosa, Alan De Prakash, Swathi J Vasc Bras Therapeutic Challenge Direct oral anticoagulants (DOACs) have become the standard of care for acute and long-term therapy for venous thromboembolism (VTE) due to their efficacy and safety profiles. The 2021 International Society on Thrombosis and Haemostasis guidelines recommend using standard DOAC dosages in patients with BMI >40 kg/m(2) or weight >120 kg. Use of DOACs remains uncertain in morbidly obese patients with VTE, including acute PE. A morbidly obese woman in her 30s who presented with acute worsening of dyspnea was diagnosed with acute intermediate-high risk acute pulmonary embolism and concomitant proximal deep vein thrombosis, constituting a clinically challenging scenario for treating her with rivaroxaban. Standard doses of rivaroxaban for acute and extended phase treatment of venous thromboembolism in individuals with morbid obesity at BMI>70 kg/m(2) may be effective, and safe. Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV) 2023-06-30 /pmc/articles/PMC10421569/ /pubmed/37576730 http://dx.doi.org/10.1590/1677-5449.202300562 Text en Copyright© 2023 The authors. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Therapeutic Challenge
Dah, Kingsley
Porres-Aguilar, Mateo
la Rosa, Alan De
Prakash, Swathi
Successful use of rivaroxaban achieving therapeutic anti-factor xa levels in a morbidly obese patient with acute intermediate-high risk pulmonary embolism
title Successful use of rivaroxaban achieving therapeutic anti-factor xa levels in a morbidly obese patient with acute intermediate-high risk pulmonary embolism
title_full Successful use of rivaroxaban achieving therapeutic anti-factor xa levels in a morbidly obese patient with acute intermediate-high risk pulmonary embolism
title_fullStr Successful use of rivaroxaban achieving therapeutic anti-factor xa levels in a morbidly obese patient with acute intermediate-high risk pulmonary embolism
title_full_unstemmed Successful use of rivaroxaban achieving therapeutic anti-factor xa levels in a morbidly obese patient with acute intermediate-high risk pulmonary embolism
title_short Successful use of rivaroxaban achieving therapeutic anti-factor xa levels in a morbidly obese patient with acute intermediate-high risk pulmonary embolism
title_sort successful use of rivaroxaban achieving therapeutic anti-factor xa levels in a morbidly obese patient with acute intermediate-high risk pulmonary embolism
topic Therapeutic Challenge
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421569/
https://www.ncbi.nlm.nih.gov/pubmed/37576730
http://dx.doi.org/10.1590/1677-5449.202300562
work_keys_str_mv AT dahkingsley successfuluseofrivaroxabanachievingtherapeuticantifactorxalevelsinamorbidlyobesepatientwithacuteintermediatehighriskpulmonaryembolism
AT porresaguilarmateo successfuluseofrivaroxabanachievingtherapeuticantifactorxalevelsinamorbidlyobesepatientwithacuteintermediatehighriskpulmonaryembolism
AT larosaalande successfuluseofrivaroxabanachievingtherapeuticantifactorxalevelsinamorbidlyobesepatientwithacuteintermediatehighriskpulmonaryembolism
AT prakashswathi successfuluseofrivaroxabanachievingtherapeuticantifactorxalevelsinamorbidlyobesepatientwithacuteintermediatehighriskpulmonaryembolism